A Phase 2 interventional study of SLIMM and Standard Resistance Training in Chronic Kidney Diseases and Obesity, sponsored by Srinvasan Beddhu. Recruiting at 2 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Srinvasan Beddhu · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing semaglutide in Renal Insufficiency, Chronic — 9 open to participants now, 9 under way, 1 of them phase 3. Semaglutide · Renal Insufficiency, Chronic.
Among the 14 studies testing semaglutide in Renal Insufficiency, Chronic, this one is the 4th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 2, and was the 3rd registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →9 of the 14 studies testing semaglutide in Renal Insufficiency, Chronic are open now, in 9 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in China
Ages 18+
Institute of Liver and Biliary Sciences, India · Sites in India
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Western University, Canada · Sites in Canada
Ages 18+
The George Institute · Sites in Australia, India, New Zealand and 2 more countries
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 156 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 77 across the 14 interventional studies. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 14 have an industry lead sponsor. The 10 most frequent:
Srinvasan Beddhu is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Srinvasan Beddhu has 3 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies testing semaglutide in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
| NCT07017270Unity Health TorontoGlucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing semaglutide in Renal Insufficiency, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, standard-of-care resistance training and oral placebo
Behavioral: SLIMM · Behavioral: Standard Resistance Training · Drug: Placebo
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral placebo
Behavioral: SLIMM · Behavioral: Guided Resistance Training · Drug: Placebo
SLIMM intervention for 3 months, followed by a 9-month intervention of SLIMM, guided resistance training and oral semaglutide
Behavioral: SLIMM · Behavioral: Guided Resistance Training · Drug: Semaglutide
Increase in light walking activity, replacing 1 hour/day of sedentary duration with casual walking duration. Increase in sedentary breaks, from sitting/lying position to standing position, at least once every hour as independent of the total time spent on sedentary activities.
Participants will be provided a standard resistance training regimen to follow during the course of the study. Participants will not receive individualized instruction, guidance or modification to the resistance training regimen.
Supervised resistance training sessions are individualized for a low-resistance, high-repetition regimen of lower body major muscle groups with established guidelines. Instructions and resistance training bands will be provided for home use. Study participants will record compliance to the resistance training regimen for further guidance and potential modification.
Oral placebo tablets (matching the experimental semaglutide) will be administered from the first through ninth months of the drug intervention period.
Oral semaglutide 3 mg/day will be administered for the first month of study drug intervention period, if tolerated, the dose will increase to 7 mg/day for the second month and to a maximum dose of 14 mg/day from the third through ninth months of the drug intervention period.
Average Change in Sedentary Duration at Months 8, 10 and 12 from Randomization
The primary analysis will provide estimates and confidence intervals for the three arms comparisons of changes in sedentary duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups that constitute the co-primary comparisons under the study design
Time frame: Randomization to 12 Months
Average Change in Steps per Day at Months 8, 10 and 12 from Randomization
The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in steps per day from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.
Time frame: Randomization to 12 Months
Average Change in Stepping Duration at Months 8, 10 and 12 from Randomization
The analysis will provide estimates and confidence intervals for the three arms comparisons of changes in stepping duration from randomization (at 3 months) to the average of changes at months 8, 10 and 12 between the randomized groups.
Time frame: Randomization to 12 Months
Average Change in Six-Minute Walk at Months 6 and 12 from Randomization
Changes in six minute walk distance from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Body Fat % at Months 6 and 12 from Randomization
Changes in average body fat percentage as measured by bioimpedance analysis from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Patient Reported Fatigue at Months 6 and 12 from Randomization
Changes in patient reported fatigue as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Patient Reported Sleep at Months 6 and 12 from Randomization
Changes in patient reported sleep as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Patient Reported Quality of Life at Months 6 and 12 from Randomization
Changes in patient reported quality of life as measured by questionaires from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Lower Extremity Performance Battery Composite Score (LEP-CS) at Months 6 and 12 from Randomization
Changes in Lower Extremity Performance Battery Composite Score (LEP-CS) from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in Circulating Protein Markers of Inflammation at Months 6 and 12 from Randomization
Changes in circulating protein markers of inflammation from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Average Change in microRNA (miRNA) Markers of Inflammation at Months 6 and 12 from Randomization
Changes in microRNA (miRNA) markers of inflammation from randomization (at 3 months) to the average of changes at months 6 and 12
Time frame: Randomization to 12 Months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.
Of 58 non-industry phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 62. This study's planned 60 months is above that.
Counting every sponsor, half of 138 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Renal Insufficiency, Chronic →
Srinvasan Beddhu